Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 5/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4297031 | 0.93 | HCRTR1 (0.39) | HCRTR1HCRTR2KDM4EALDH1A1 | |
| SCHEMBL4285677 | 0.91 | HCRTR1 (0.39) | HCRTR1HCRTR2KDM4EMEN1ALDH1A1 | |
| SCHEMBL4285267 | 0.91 | HCRTR1 (0.36) | HCRTR1HCRTR2KDM4EMEN1ALDH1A1 | |
| SCHEMBL4286213 | 0.90 | HCRTR1 (0.35) | HCRTR1HCRTR2 | |
| SCHEMBL4296767 | 0.90 | HCRTR1 (0.34) | HCRTR1HCRTR2 | |
| SCHEMBL4282962 | 0.89 | HCRTR1 (0.34) | HCRTR1HCRTR2MEN1ALDH1A1KMT2A | |
| SCHEMBL4284990 | 0.89 | HCRTR1 (0.32) | HCRTR1HCRTR2 | |
| SCHEMBL4281791 | 0.89 | HCRTR2 (0.33) | HCRTR1HCRTR2 | |
| SCHEMBL4286693 | 0.89 | HCRTR1 (0.34) | HCRTR1HCRTR2MEN1ALDH1A1KMT2A | |
| SCHEMBL4284953 | 0.88 | USP19 (0.36) | HCRTR1HCRTR2SSTR4KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HCRTR1 3147/4885HCRTR2 3136/4885SSTR4 945/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HCRTR1 3147/4885HCRTR2 3136/4885SSTR4 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.